OpenLB
Open Library of Bioscience
Advanced Search
Canadian journal of kidney health and disease
2020;7 2054358120962589.

Perspectives From an Onconephrology Interest Group: Conference Report.

Abhijat Kitchlu, Christopher T Chan, Nelson Leung, Sheldon Chen, Sheron Latcha, Paul Tam
Author Information
  1. Abhijat Kitchlu: Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, ON, Canada. ORCID
  2. Christopher T Chan: Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, ON, Canada.
  3. Nelson Leung: Department of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
  4. Sheldon Chen: Department of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
  5. Sheron Latcha: Renal Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  6. Paul Tam: Department of Medicine, Division of Nephrology, The Scarborough Hospital, Toronto, ON, Canada.
PMID: 33117547 DOI: 10.1177/2054358120962589

Abstract

INTRODUCTION AND OBJECTIVE: Onconephrology is a new and evolving field that deals with kidney complications in patients with cancer as well as the management of cancer in patients with preexisting kidney disease. With increasing numbers of patients with cancer with kidney-related complications, the field has garnered increased attention. Thus, an annual Greater Toronto Area Onconephrology Interest Group symposium was held in May 2019. The objective of the meeting was to demonstrate the junctures between oncology and nephrology by highlighting recent data regarding (1) kidney impairment in solid organ malignancies, (2) management and treatment of kidney cancer, (3) kidney impairment in hematologic malignancies, (4) malignancy and kidney transplantation, and (5) hyponatremia in patients with cancer.
METHODS AND SOURCES OF INFORMATION: Through a structured presentation, the group explored key topics discussed at a Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Onconephrology. Expert opinions, clinical trial findings, and publication summaries were used to illustrate patient and treatment-related considerations in onconephrology.
KEY FINDINGS: Kidney complications in patients with cancer are a central theme in onconephrology. An estimated 12% to 25% of patients with solid organ malignancies have chronic kidney disease (CKD), although in certain cancers, the prevalence of CKD is higher. Kidney impairment is also a common complication of some hematologic malignancies. The incidence of renal failure in patients with multiple myeloma is estimated at 18% to 56% and light chain cast nephropathy is seen in approximately 30% of these patients. In addition, there appears to be a bidirectional relationship between kidney cancer and CKD, with some data sets suggesting the risk increases as kidney function declines. Cancer is also of concern in patients with preexisting kidney disease. Kidney transplant recipients have a greater risk of cancer and a higher risk of cancer-related mortality. Kidney complications have also been associated with novel cancer therapies, such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy. An estimated 2% to 4% of patients initiating an immune checkpoint inhibitor may develop nephrotoxicity, whereas up to 40% of patients on CAR T-cell therapy experience cytokine release syndrome (CRS). Tumor lysis syndrome and electrolyte abnormalities, such as hyponatremia, have also been reported with CAR T-cell therapy. While the incidence and prevalence of hyponatremia vary depending on the cancer type and serum sodium cutoff point, hyponatremia may be seen in up to 46% of patients hospitalized in cancer centers.
CONCLUSIONS: Onconephrology is a developing field and the themes arising from this meeting indicate a need for greater collaboration between oncologists and nephrologists. Educational symposia and onconephrology fellowship programs may allow for improved cancer care for patients with kidney disease.

Keywords

cancer chronic kidney disease myeloma cast nephropathy nephrotoxicity onconephrology

References

Br Med J. 1976 Feb 28;1(6008):503-4 [PMID: 1252820]
Kidney Int. 2014 May;85(5):1002-4 [PMID: 24786870]
Eur Urol. 2015 Dec;68(6):996-1003 [PMID: 26012710]
Br J Cancer. 2010 Dec 7;103(12):1815-21 [PMID: 21063408]
Clin J Am Soc Nephrol. 2009 Apr;4(4):745-54 [PMID: 19339414]
Blood. 2017 Nov 23;130(21):2295-2306 [PMID: 28924019]
Am J Kidney Dis. 2015 May;65(5):763-72 [PMID: 25662835]
J Am Soc Nephrol. 2011 Jun;22(6):1129-36 [PMID: 21511832]
Urology. 2011 Nov;78(5):1089-94 [PMID: 22054378]
Lancet Haematol. 2019 Apr;6(4):e217-e228 [PMID: 30872075]
Am J Kidney Dis. 2019 Mar;73(3 Suppl 1):A7-A8 [PMID: 30798791]
Nat Rev Nephrol. 2014 Mar;10(3):135-45 [PMID: 24419566]
Clin J Am Soc Nephrol. 2017 Jan 6;12(1):95-104 [PMID: 28034851]
Blood Cancer J. 2017 Apr 21;7(4):e554 [PMID: 28430175]
BMC Nephrol. 2018 Jul 13;19(1):178 [PMID: 30012107]
Clin J Am Soc Nephrol. 2018 May 7;13(5):796-798 [PMID: 29523675]
Nephrol Dial Transplant. 2003 Mar;18(3):598-603 [PMID: 12584285]
JAMA. 2018 Jun 19;319(23):2437-2439 [PMID: 29922818]
Clin J Am Soc Nephrol. 2016 Feb 5;11(2):344-53 [PMID: 26450932]
J Clin Oncol. 2010 Mar 20;28(9):1599-605 [PMID: 20177027]
J Clin Oncol. 2018 Jun 10;36(17):1714-1768 [PMID: 29442540]
J Am Soc Nephrol. 2014 Oct;25(10):2327-34 [PMID: 24876115]
J Immunother Cancer. 2018 Jun 15;6(1):56 [PMID: 29907163]
Adv Chronic Kidney Dis. 2018 Jan;25(1):49-56 [PMID: 29499887]
Haematologica. 2014 Jan;99(1):148-54 [PMID: 23996482]
Ann Oncol. 2015 Oct;26(10):2155-61 [PMID: 26216382]
EMBO Mol Med. 2017 Sep;9(9):1183-1197 [PMID: 28765140]
Ann Intern Med. 2007 Mar 20;146(6):471 [PMID: 17402169]
Can Urol Assoc J. 2010 Oct;4(5):337-43 [PMID: 20944808]
Haematologica. 2006 Nov;91(11):1498-505 [PMID: 17043025]
Nat Rev Nephrol. 2018 Sep;14(9):571-588 [PMID: 30013100]
Ann Intern Med. 2018 Jan 16;168(2):121-130 [PMID: 29297009]
Am J Med. 2009 Sep;122(9):857-65 [PMID: 19699382]
N Engl J Med. 2018 Jan 11;378(2):158-168 [PMID: 29320654]
Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1641-1648 [PMID: 30266837]
Semin Nephrol. 2010 Nov;30(6):548-56 [PMID: 21146120]
J Am Soc Nephrol. 2019 Mar;30(3):471-480 [PMID: 30765426]
Nihon Jinzo Gakkai Shi. 2011;53(1):38-45 [PMID: 21370576]
Br J Haematol. 2004 Oct;127(1):3-11 [PMID: 15384972]
Kidney Int. 2016 Sep;90(3):638-47 [PMID: 27282937]
Am J Kidney Dis. 2014 Jan;63(1):23-30 [PMID: 23993153]
JAMA Oncol. 2016 Apr;2(4):463-9 [PMID: 26746479]
Ann Oncol. 2019 May 1;30(5):706-720 [PMID: 30788497]
Semin Oncol. 2010 Oct;37(5):430-9 [PMID: 21074057]
Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1057-1069 [PMID: 28483780]
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62 [PMID: 28925994]
J Natl Cancer Inst. 2019 Jul 1;111(7):727-736 [PMID: 30423160]
Nat Clin Pract Nephrol. 2008 Jun;4(6):337-41 [PMID: 18414461]
Cancer. 2007 Sep 15;110(6):1376-84 [PMID: 17634949]
Kidney Int. 2008 Jun;73(11):1282-8 [PMID: 18385667]
Oncologist. 2012;17(6):756-65 [PMID: 22618570]
J Clin Oncol. 2010 Oct 20;28(30):4621-9 [PMID: 20823406]
JAMA. 2017 Dec 5;318(21):2099-2110 [PMID: 29209721]
J Am Soc Nephrol. 2018 Aug;29(8):2039-2052 [PMID: 29959196]
J Urol. 2014 Mar;191(3):619-25 [PMID: 24036234]
CMAJ. 2014 May 13;186(8):E281-6 [PMID: 24344146]
J Clin Invest. 1958 Sep;37(9):1236-56 [PMID: 13575523]

Grants

  1. P30 CA008748/NCI NIH HHS
Journal Article

Word Cloud

Similar Articles

Cited By